A recently published report describes the case of a 59-year-old male patient who experienced olmesartan-associated enteropathy (OAE) and highlights the importance of performing thorough medication reviews.
Finch Therapeutics announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CP101 for the treatment of patients with recurrent Clostridium difficile (C. difficile) infection.
The investigational drug is currently in Phase 1 development, with completion expected in the second quarter of 2019.
No benefits seen with Lactobacillus rhamnosus GG or L. rhamnosus R0011 and L. helveticus R0052
Aemcolo is a broad spectrum, semi-synthetic, orally-administered, minimally-absorbed antibiotic designed to allow for delayed release to the colon.
A Phase 3 clinical trial of patients with travelers’ diarrhea demonstrated that Aemcolo was superior to placebo (P=.0008) and non-inferior to ciprofloxacin.
Firvanq will replace CutisPharma’s FIRST-Vancomycin Unit-of-Use Compounding Kit.
There was no significant difference between the two therapies in odds ratios for efficacy, diarrhea, or diarrhea-related study withdrawals.
The FDA will be working with manufacturers to use blister packs or other single-dose packaging in efforts to limit the number of doses in a package.
Diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older.
